---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-26-000053"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2026-06-01T20:28:49+00:00"
generated_at: "2026-06-01T20:37:46.199296+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Praxis Precision Medicines: Phase 2/3 vormatrigine study fails primary endpoint in focal seizures

## Summary
- POWER1 study of vormatrigine in focal onset seizures did not meet primary success measure.
- Secondary 50% response rate achieved; higher 30 mg dose showed more pronounced seizure reduction in second half.
- Vormatrigine well-tolerated with <10% adverse event-related discontinuations; ~90% entered open-label extension.
- Company pausing enrollment in POWER2 study to reassess vormatrigine program and potential modifications.

## SEC filing metadata
- accession: 0001689548-26-000053
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2026-06-01T20:28:49+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/0001689548-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/prax-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-26-000053
- JSON: https://secwatch.observer/filing/0001689548-26-000053.json
- Plain text: https://secwatch.observer/filing/0001689548-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.